drugset
drugset / Trial / NCT04477629

Belatacept in De Novo Heart Transplantation

NCT04477629 ↗

Phase 2 Recruiting 12 enrolled NYU Langone Health Bristol-Myers Squibb · collab
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to determine if Belatacept is safe to give to adult heart transplant recipients. Belatacept (NULOJIX) is an anti-rejection medication that is available through a prescription from a doctor. In this research study, belatacept is being used in an investigational manner (not for the purpose that it is approved for).

Timeline

Start
2020-08-06
Primary completion
2026-09
Completion
2026-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Belatacept Protein / enzyme biologic 5 mg/kg Intravenous
Background Mycophenolate Mofetil Small molecule 500 mg —
Background Mycophenolate Mofetil Small molecule 1500 mg —
Background Tacrolimus Small molecule — —

Indications

No indication recorded.